Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | FABP7 | O15540 | 2/20 | 0.44 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.44 |
| ▸ | CASP3 | P42574 | 2/20 | 0.43 |
| ▸ | MDM4 | O15151 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30421786 | 1.00 | KMT2A (0.56) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL27645062 | 0.85 | KMT2A (0.52) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL26140029 | 0.85 | KMT2A (0.59) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL18687752 | 0.84 | KMT2A (0.55) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL525568 | 0.84 | KMT2A (0.58) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL29097418 | 0.83 | KMT2A (0.59) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL2744610 | 0.83 | KMT2A (0.54) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL7920181 | 0.83 | KMT2A (0.52) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL28330792 | 0.83 | KMT2A (0.49) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL3177417 | 0.82 | KMT2A (0.62) | KMT2AEPHX2FABP7FABP5CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116535459-A | Phenolic acid compound and synthesis method and application thereof | 西北大学 | 2023-08-04 | — | — | CN | claimed |
| US-20250108138-A1 | THERAGNOSTIC FOLATE CONJUGATES | MERCK PATENT GMBH (DE) | 2025-04-03 | — | — | US | disclosed |
| EP-4472676-A1 | THERAGNOSTIC FOLATE CONJUGATES | Merck Patent GmbH (DE) | 2024-12-11 | — | — | EP | disclosed |
| CN-118660723-A | Therapeutic diagnostic folate conjugates | 默克专利股份有限公司 | 2024-09-17 | — | — | CN | disclosed |
| WO-2023148115-A1 | THERAGNOSTIC FOLATE CONJUGATES | MERCK PATENT GMBH (DE) | 2023-08-10 | — | — | WO | disclosed |
| CN-116535459-A | Phenolic acid compound and synthesis method and application thereof | 西北大学 | 2023-08-04 | — | — | CN | disclosed |
| CN-113646329-A | Glucose-sensitive insulin derivatives | 诺和诺德股份有限公司 | 2021-11-12 | — | — | CN | disclosed |
| US-8895231-B2 | Patterning process and resist composition | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2014-11-25 | — | — | US | disclosed |
| US-8895231-B2 | Patterning process and resist composition | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2014-11-25 | — | — | US | disclosed |
| US-20130136691-A1 | GASTRIN RELEASING PEPTIDE COMPOUNDS | BRACCO IMAGING S.P.A. (IT) | 2013-05-30 | — | — | US | disclosed |
| US-7611692-B2 | bombesin, derivatives and/or analogues capable of complexing metal ions, radionuclides or optical labels, for use in radiotherapy | BRACCO IMAGING S.P.A. (IT) | 2009-11-03 | — | — | US | disclosed |
| US-20090175786-A1 | Gastrin Releasing Peptide Compounds | BRACCO IMAGING S.P.A. (IT) | 2009-07-09 | — | — | US | disclosed |
| US-20080247946-A1 | Bombesin capable of complexing with metal ions, radionuclides, or optical labels; radiotherapy | BRACCO IMAGING S.P.A. (IT) | 2008-10-09 | — | — | US | disclosed |
| US-20080008649-A1 | Gastrin Releasing Peptide Compounds | BRACCO IMAGING S.P.A. (IT) | 2008-01-10 | — | — | US | disclosed |
| WO-2007117404-A9 | METHODS AND MATERIALS FOR PREPARING ORGANIC COMPOUNDS FROM PRIMARY AMINES | UNIV VIRGINIA (US) | 2007-11-29 | — | — | WO | disclosed |
| WO-2007117404-A2 | METHODS AND MATERIALS FOR PREPARING ORGANIC COMPOUNDS FROM PRIMARY AMINES | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2007-10-18 | — | — | WO | disclosed |
| US-7226577-B2 | Gastrin releasing peptide compounds | BRACCO IMAGING, S. P. A. (IT) | 2007-06-05 | — | — | US | disclosed |
| US-20050019831-A1 | Facilitated forward chemical genetics using tagged triazine library | NEW YORK UNIVERSITY (US) | 2005-01-27 | — | — | US | disclosed |
| WO-2004099106-A2 | FACILITATED FORWARD CHEMICAL GENETICS USING TAGGED TRIAZINE LIBRARY | NEW YORK UNIVERSITY (US) | 2004-11-18 | — | — | WO | disclosed |
| US-6034056-A | CYCLIC PEPTIDES; ANTIARTHRITIC AGENTS | ZENECA LIMITED (GB) | 2000-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250108138-A1 | THERAGNOSTIC FOLATE CONJUGATES | FOLR1, MTHFD1, MTHFD2 | KMT2A 1726/4885EPHX2 992/4885FABP7 43/4885 |
| US-20130136691-A1 | GASTRIN RELEASING PEPTIDE COMPOUNDS | GRPR, GIPR, GHRHR | KMT2A 4582/4885EPHX2 4140/4885FABP7 336/4885 |
| US-20090175786-A1 | Gastrin Releasing Peptide Compounds | GRPR, SSTR5, GIPR | KMT2A 2078/4885EPHX2 3872/4885FABP7 300/4885 |
| US-20080008649-A1 | Gastrin Releasing Peptide Compounds | GRPR, SSTR5, GIPR | KMT2A 2078/4885EPHX2 3872/4885FABP7 300/4885 |
| US-20080247946-A1 | Bombesin capable of complexing with metal ions, radionuclides, or optical labels; radiotherapy | GRPR, MRGPRX1, BRS3 | KMT2A 4425/4885EPHX2 3747/4885FABP7 627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.